Chris Bunge

Hedge fund analyst, long/short equity
Chris Bunge
Hedge fund analyst, long/short equity
Contributor since: 2013
Ziopharm: Why Is No One Modeling The 'New' Ziopharm?
Intrexon: Energy Segment Could Be Potential Blockbuster
Energy Recovery, Inc.: Inflection Point Is Here
Alcobra: The Next Big Thing In ADHD
ANI Pharmaceuticals: Nothin' Generic About It
ATMI: On The Cusp Of A Major Revaluation
Aceto: A Generic-Drug Growth Story